Goldkast-L Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated for the effective management of allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria associated with allergic rhinitis and chronic idiopathic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, preventing bronchoconstriction, inflammation, and mucus production, making it beneficial in the prophylaxis and treatment of asthma and allergic rhinitis. The synergistic action of these two agents provides comprehensive relief from allergic symptoms by targeting multiple inflammatory pathways. Goldkast-L is indicated for patients requiring combined antihistaminic and leukotriene receptor antagonist therapy, particularly in cases where monotherapy is insufficient. It is generally well-tolerated, with a favorable safety profile; common adverse effects may include headache, fatigue, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision. Goldkast-L Tablet offers an effective therapeutic option for improved symptom control in allergic respiratory diseases and related hypersensitivity disorders.